Search results
Kiniksa Highlights ARCALYST Growth as KPL-387 Advances Into Phase 3
Key Points
- Interested in Kiniksa Pharmaceuticals International, plc? Here are five stocks we like better.
- ARCALYST revenue growth accelerated: Kiniksa reported approximately $243 million in
NXP Semiconductors Sees Demand Rebound as Auto, AI and Data Center Growth Accelerate
Key Points
- Interested in NXP Semiconductors N.V.? Here are five stocks we like better.
- Demand is rebounding across NXP’s markets: Book-to-bill ratios are above one, distribution inventory has

